Jesper Dahl

630 total citations · 1 hit paper
20 papers, 365 citations indexed

About

Jesper Dahl is a scholar working on Infectious Diseases, Epidemiology and Hematology. According to data from OpenAlex, Jesper Dahl has authored 20 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 4 papers in Epidemiology and 4 papers in Hematology. Recurrent topics in Jesper Dahl's work include SARS-CoV-2 and COVID-19 Research (5 papers), Influenza Virus Research Studies (4 papers) and Platelet Disorders and Treatments (4 papers). Jesper Dahl is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (5 papers), Influenza Virus Research Studies (4 papers) and Platelet Disorders and Treatments (4 papers). Jesper Dahl collaborates with scholars based in Norway, Sweden and Denmark. Jesper Dahl's co-authors include Hanne Løvdal Gulseth, Øystein Karlstad, Anders Hviid, Jesper Hallas, Øjvind Lidegaard, Anders Pretzmann Mikkelsen, Henrik Toft Sørensen, Reimar W. Thomsen, Anton Pottegård and Sara Viksmoen Watle and has published in prestigious journals such as SHILAP Revista de lepidopterología, European Heart Journal and BMJ.

In The Last Decade

Jesper Dahl

18 papers receiving 356 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

2021 266 citations Anton Pottegård, Lars Christian Lund et al. BMJ profile →

Peers

Countries citing papers authored by Jesper Dahl

Since Specialization

Citations

This map shows the geographic impact of Jesper Dahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesper Dahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesper Dahl more than expected).

Fields of papers citing papers by Jesper Dahl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesper Dahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesper Dahl. The network helps show where Jesper Dahl may publish in the future.

Co-authorship network of co-authors of Jesper Dahl

This figure shows the co-authorship network connecting the top 25 collaborators of Jesper Dahl. A scholar is included among the top collaborators of Jesper Dahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesper Dahl. Jesper Dahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Low and inequitable influenza and COVID-19 vaccination coverage among pregnant women in Norway: Nationwide population-based cohort study 2025 ·Vaccine ·Bo T. Hansen, Jesper Dahl, Margrethe Greve‐Isdahl, Brita Askeland Winje, (unknown), Suzanne Hetzel Campbell, Aase Serine Devold Pay, (unknown), Hinta Meijerink	1
2	SARS-CoV-2 vaccination and myositis in Norway and Sweden 2025 ·Lara D. Veeken ·Rickard Ljung, Nicklas Pihlström, Jesper Dahl, German Tapia, Anders Sundström, Marja‐Leena Nurminen, Ingrid E. Lundberg, Øystein Karlstad, Marie Holmqvist, Nils Feltelius	0
3	Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis 2025 ·Neurology Neuroimmunology & Neuroinflammation ·Jesper Dahl, (unknown), Christopher Winter, (unknown), Veit Rothhammer, (unknown), Anne‐Katrin Pröbstel, Tradite Neziraj, (unknown), Johanna Oechtering, Jens Kühle, (unknown), (unknown), (unknown), Luisa Klotz, (unknown), Stefanie Küerten	4
4	Statin Use and Amyotrophic Lateral Sclerosis Survival: A Population‐Based Cohort Study 2025 ·European Journal of Neurology ·(unknown), Trygve Holmøy, Jesper Dahl, Hein Stigum, Helmut E. Meyer, (unknown)	2
5	Changed epidemiology of influenza and RSV hospitalizations after the emergence of SARS-CoV-2 in Norway, 2017–2024 2025 ·Annals of Epidemiology ·Håkon Bøås, Elina Seppälä, Lamprini Veneti, (unknown), (unknown), Jesper Dahl, (unknown)	0
6	Registry‐Based Surveillance of Severe Acute Respiratory Infections in Norway During 2021–2024 2025 ·Influenza and Other Respiratory Viruses ·Elina Seppälä, Håkon Bøås, Jesper Dahl, (unknown), Melanie Stecher, Ragnhild Tønnessen, Gunnar Rø, Hilde Kløvstad, (unknown)	2
7	Dietary inflammatory pattern and risk of hip fracture in the Nurses’ Health Study 2024 ·Archives of Osteoporosis ·Jesper Dahl, Helmut E. Meyer, Fred K. Tabung, Walter C. Willett, Kristin Holvik, Teresa T. Fung	2
8	Booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis in adolescents and young adults: a Nordic cohort study 2024 ·European Heart Journal ·Anders Hviid, (unknown), Nicklas Pihlström, Nina Gunnes, Jesper Dahl, Øystein Karlstad, Hanne Løvdal Gulseth, Anders Sundström, Anders Husby, Jørgen Vinsløv Hansen, Rickard Ljung, Petteri Hovi	12
9	Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study 2023 ·SHILAP Revista de lepidopterología ·Anders Husby, Hanne Løvdal Gulseth, Petteri Hovi, Jørgen Vinsløv Hansen, Nicklas Pihlström, Nina Gunnes, Tommi Härkänen, Jesper Dahl, Øystein Karlstad, Tiina Heliö, Lars Køber, Rickard Ljung, Anders Hviid	20
10	Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023 2023 ·Vaccine ·Elina Seppälä, Jesper Dahl, Lamprini Veneti, (unknown), (unknown), (unknown), Hinta Meijerink	8
11	Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway 2022 ·Vaccine ·Paz Lopez‐Doriga Ruiz, Nina Gunnes, Jon Michael Gran, Øystein Karlstad, Randi Selmer, Jesper Dahl, Håkon Bøås, Richard White, (unknown), (unknown), Sara Viksmoen Watle, Anette Hylen Ranhoff, Geir Bukholm, Hanne Løvdal Gulseth, German Tapia	5
12	Strong tuberculin response after BCG vaccination is associated with low multiple sclerosis risk: a population-based cohort study 2022 ·International Journal of Epidemiology ·(unknown), Trygve Holmøy, Hein Stigum, Kjell‐Morten Myhr, Jesper Dahl, Einar Heldal, Helmut E. Meyer	5
13	Risk of hip and forearm fracture in subjects with type 2 diabetes mellitus and latent autoimmune diabetes of adults. The HUNT Study, Norway 2021 ·Bone ·Jesper Dahl, Hanne Løvdal Gulseth, Lisa Forsén, Mari Hoff, Siri Forsmo, Bjørn Olav Åsvold, Berit Schei, Kristian Midthjell, Helmut E. Meyer	2
14	Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study breakdown → 2021 ·BMJ ·Anton Pottegård, Lars Christian Lund, Øystein Karlstad, Jesper Dahl, Morten Andersen, Jesper Hallas, Øjvind Lidegaard, German Tapia, Hanne Løvdal Gulseth, (unknown), Sara Viksmoen Watle, Anders Pretzmann Mikkelsen, Lars Pedersen, Henrik Toft Sørensen, Reimar W. Thomsen, Anders Hviid	266
15	Individual Variation in Adaptive Immune Responses and Risk of Hip Fracture—A NOREPOS Population-Based Cohort Study 2020 ·Journal of Bone and Mineral Research ·Jesper Dahl, Kristin Holvik, Einar Heldal, Guri Grimnes, Mari Hoff, Trine Finnes, Ellen M. Apalset, Helmut E. Meyer	1
16	A combined effect of anti‐HPA‐1a and anti‐HLA Class I in pregnancy? 2020 ·Transfusion ·Jesper Dahl, Bjøŕn Skogen, Mette Kjær, Anne Husebekk, Jens Kjeldsen‐Kragh, Heidi Tiller	3
17	Unraveling the role of maternal anti-HLA class I antibodies in fetal and neonatal thrombocytopenia—Antibody specificity analysis using epitope data 2017 ·Journal of Reproductive Immunology ·Jesper Dahl, Erle Refsum, Maria Therese Ahlén, Torstein Egeland, Tore Jensen, Marte K. Viken, Tor B. Stuge, Ganesh Acharya, Anne Husebekk, Bjøŕn Skogen, Heidi Tiller	13
18	Characterisation of maternal human leukocyte antigen class I antibodies in suspected foetal and neonatal alloimmune thrombocytopenia 2016 ·Transfusion Medicine ·Erle Refsum, Anette Mörtberg, Jesper Dahl, Stephan Meinke, (unknown), Magnus Westgren, Marie Reilly, Petter Höglund, Agneta Wikman	7
19	Maternal anti-HLA class I antibodies are associated with reduced birth weight in thrombocytopenic neonates 2015 ·Journal of Reproductive Immunology ·Jesper Dahl, Anne Husebekk, Ganesh Acharya, Kari Flo, Tor B. Stuge, Bjøŕn Skogen, Bjørn Straume, Heidi Tiller	9
20	[Prevention of premature labor by means of supporting pessaries (1st experiences)]. 1979 ·PubMed ·Jesper Dahl, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact